PropertyValue
?:abstract
  • A \'standard\' emerges CAR T-cell therapies now are FDAapproved for relapsed aggressive B-cell lymphoma and data are beginning to emerge for patients treated as standard of care A patient population with a median age of 60 years, in which more than 80% have an ECOG performance status of 0 or 1, is still highly selected, but even someone as curmudgeonly as me cant fail to be excited and impressed by these unprecedented outcomes in a challenging clinical situation Patients with relapsed and refractory multiple myeloma - particularly those with penta-refractory disease - represent a very challenging patient population for which there is intense interest in the use of CAR T cells
?:creator
?:journal
  • HEM/ONC_Today
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Who\'s driving the CARs in the race?
?:type
?:who_covidence_id
  • #941035
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/64j5w520>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/64j5w520>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all